Keynote Speaker:

          H.Carl McCall, State Comptroller, State of New York

         "New York Welcomes Global Private Equity Investors"   

        H.Carl McCall has served as Comptroller of the State of New York since May, 1993, when he was elected by the New York State Legislature to fill an unexpired term. He was elected by the voters of New York in 1994 and re-elected in November, 1998 when he received 2.9 million votes, more than any other statewide candidate. As Chief Fiscal Officer of the State, he is responsible for governmental and financial oversight and pension fund management. Comptroller McCall audits the spending practices of the State and public authorities and 1,600 cities, counties, towns and villages across New York State. As sole trustee of the 880,000-member State and Local Retirement Systems, Mr. McCall is responsible for investing a pension fund valued at more than $112 billion. Mr. McCall has had a distinguished career as a public servant. From 1991 to 1993, he served as President of the New York City Board of Education where he set policy for the largest school system in the nation. He served three terms as a New York State Senator representing the upper Manhattan district of New York City; as an Ambassador to the United Nations; as a Commissioner of the Port Authority of New York and New Jersey; and as the Commissioner of the New York State Division of Human Rights. From 1985 to 1993, Mr. McCall served as Vice-President of Citicorp/Citibank. In June, 1999, Mr. McCall was elected to the board of the New York Stock Exchange. He is the only public official on the 26 member board. Mr. McCall is a member of the Council on Foreign Relations and is the recipient of numerous awards, including the 1997 Nelson A. Rockefeller Award for Distinguished Public Service. Mr. McCall was educated at Dartmouth College, Andover Newton Theological Seminary and the University of Edinburgh.

For more information, visit www.osc.state.ny.us/about/bio.htm

___________________________________________________________________

    Kohlberg & Company, L.L.C. is one of the most widely known U.S. private equity firms specializing in middle market investing. Since its founding in 1987, the firm’s objective has been to realize substantial capital gains through control investments in a diversified portfolio of companies.  The firm’s goals are to increase revenues through enhanced marketing, investment in new products and selected strategic acquisitions, and to increase profitability through cost reductions and operational improvements.  The firm has completed 30 platform investments and more than 60 add-on acquisitions with an aggregate transaction value in excess of $4.0 billion.  Selected industries Kohlberg has invested in include: general manufacturing, machinery and equipment, building products, food and food related, aerospace/defense, healthcare, consumer products, automotive, and value added services.

For more information, visit www.kohlberg.com


M.D. Sass & Co. 

         Hugh R. Lamle, President, M.D. Sass & Resurgence Asset Management

       Hugh R. Lamle is President of M.D. Sass Investors Services, Inc., a registered Investment Advisor, whose clients include substantial pension and profit sharing funds, insurance companies, Nuclear Decommissioning Trusts, endowment and charitable funds, major corporations and substantial individual portfolios, and foreign investors' portfolios. Mr. Lamle is also President of Re/Enterprise Asset Management and Resurgence Asset Management. Re/Enterprise manage distressed securities portfolios for partnerships and separate accounts in a liquid “hedge fund” format. Resurgence manages control oriented distressed portfolios in a “private equity” fund. At M.D. Sass, he is responsible for the formulation of investment policy and strategy, directing the firm's management of debt securities portfolios, hedged equities and directing the firm's research on options, financial futures, financial analysis models, applications of quantitative analysis for investment research and portfolio management and the development of alternative investment strategies.  From 1995 to 2001, Mr. Lamle was also President, Chief Investment Officer and Chief Executive Officer of Chase & MD Sass Partners, a joint venture between The Chase Manhattan Bank and M.D. Sass Investors Services, Inc.  Chase & MDSass Partners managed cash, short and intermediate term portfolios for Chase and corporate and institutional clients as well as a broad range of non-Chase related corporate, financial institution, government, charitable and high net worth individuals.  Mr. Lamle serves on the Partnership Board of Real Estate Capital Partners (RECAP). RECAP is a joint venture affiliate of M.D. Sass and invests in net lease, development and special situation real estate.  He is was formerly Vice Chairman of the Board of Directors of the FINEX (a regulated Commodities Exchange)  He is a Public Director of the New York Board of Trade (a regulated Commodities Exchange) and a member of the Board of Directors of Quelsys (a privately owned educational software company) and a Director of Coolsavings Inc. (the leading provider of incentive marketing promotions on the internet). 

        Prior to joining M.D. Sass in 1974, he was responsible for founding Lenox Capital Management, the investment advisory affiliate of duPont Glore Forgan.  Prior to Lenox Capital Management's formulation, he managed the partner's capital for Francis I. duPont (which, at that time, was the third largest brokerage firm in the US). He is a member of the New York Society of Security Analysts, the New York Institutional Options Society, the International Association for Financial Engineers, an honorary member of Beta Gamma Sigma (the national academic honor society for business degree students), and is a Fellow in the Financial Analysts Federation. He is also a Trustee of the Citizens Budget Commission. He has lectured frequently at universities and professional forums on investments and has authored numerous articles on investments for professional journals.  He is frequently quoted in newspapers and magazines and has appeared on financial television programs as well as network news programs.  He has provided financial consulting and expert witness testimony on financial and securities matters in Federal and local cases. He received a B.A. in Political Science and Economics from Queens College, and M.B.A. in Finance and Investments from Baruch College of the City University of New York.

For more information, visit www.mdsass.com


Soros Private Equity Partners
   
        David Wassong, Partner, Soros Private Equity Partners   

        David K. Wassong, a Partner in New York, has been with Soros Private Equity Partners since July 1998 and focuses on the media, entertainment and telecommunications industries.  Prior to joining SPEP, Mr. Wassong was with Lauder Gaspar Ventures from 1997 to 1998, where he participated on teams which invested in the telecommunications industry.  From 1992 to 1995, Mr. Wassong was in investment banking with Wertheim Schroder in the Media and Entertainment group.  Mr. Wassong earned his B.S. from the University of Pennsylvania and received his M.B.A. from the Wharton School of Business. 

      Soros Private Equity Partners LLC, an investment affiliate of Soros Fund Management LLC, is responsible for making direct equity investments on behalf of Soros Private Equity Investors LP as well as for the multi-billion dollar Quantum Group of Funds.  Soros Fund Management is the well-known investment advisory firm founded by George Soros.


Trident Capital

       Venetia Kontogouris, Managing Director, Trident Capital       

       Venetia Kontogouris  joined Trident Capital (www.tridentcap.com) in 1999 as a Managing Director.  Prior to joining Trident Capital, Ms. Kontogouris was President of Enterprise Associates, LLC, the venture capital division of IMS Health Incorporated, and has held various positions in venture capital since 1989.Formerly, she was Senior Vice President, Venture Development with Cognizant Corporation where she represented Cognizant in the Information Partners Capital Fund, a venture capital fund formed by Dun & Bradstreet and Bain Capital, with emphasis on the information industry and leveraged buyouts.Ms. Kontogouris has held executive positions in new product development and marketing at D&B where she was head of product development for Dun’s Marketing Services and Director of Marketing for national accounts and financial services.She also held sales management positions for AT&T and IBM.Ms. Kontogouris has also launched her own start-up company in the telecommunications industry.Ms. Kontogouris serves on the Board of Directors of Aptegrity Inc., Berkeley Enterprise Partners, Inc., C-7 Group, Inc., CentrPort, Inc., Cognizant Technology Solutions (CTSH), eCredit.com, Inc., Event Zero, Questra Corporation, Saleshound.com, Inc., T.R.A.D.E., Inc., Vality Technology, Inc. and Viant Corporation (VIAN).Ms. Kontogouris was a former Director of Avesta Technologies, Inc., Customer Analytics, Inc., eData Resources, Inc., Internet Profiles Corporation, OneSource Information Services, Inc., Jostens Learning Corporation and WEFA (Wharton Econometric Forecasting Associates).  Ms. Kontogouris earned a B.A. from Northeastern University and her M.B.A. from the University of Chicago.  

        Trident Capital is a private equity firm focused on the networked economy. In 1993, we founded Trident Capital with a clear vision: to invest in information and business services companies.  We made it our business to understand the markets, the movers, the technology and the potential. Our focus on information and business services led us to become early investors in Internet companies, including MapQuest and CSG Systems. To date, we've raised five funds and have over $1.4 billion under management. We continue to back businesses that capitalize on the ever-growing importance of information connectivity. By leveraging our operating experience and influential contacts, we've helped talented entrepreneurs to build many successful companies. A number of companies from our earlier funds are now public. Many of our recent investments are becoming leaders in their marketplaces. Investment sectors on our radar screen include: the Internet; infrastructure management; outsourcing; transaction services; wireless and information technology.

For more information, visit www.tridentcap.com.  


Trimaran Capital Partners

         Dean C. Kehler, Co-Founder & Partner, Trimaran Capital Partners 

       Mr. Kehler is a founder of Trimaran Capital Partners, a private asset management firm with over $4 billion under management. Trimaran Capital Partners manages its second private equity fund, Trimaran Fund II, a $1.043 billion fund that concentrates on investments in the equity of private companies in the United States and Western Europe. In addition to its private equity funds, Trimaran Capital Partners also manages, through Trimaran Advisors, a portfolio of structured investment funds. Mr. Kehler is also a vice-chairman of CIBC World Markets Corp., co-head of CIBC World Markets High Yield Merchant Banking Funds, and a member of CIBC's Executive Board, U.S. Management Committee and Investment Committee. Prior to joining CIBC in 1995, Mr. Kehler was a founder and managing director of The Argosy Group L.P. Mr. Kehler serves as a director of Heating Oil Partners L.P., First Knowledge Partners, Booth Creek Holdings, inviva, inc., and CityNet Telecommunications, Inc. Mr. Kehler received his B.S. degree from The Wharton School of the University of Pennsylvania.

  Trimaran Capital Partners is a private asset management firm established in 2000 by Jay R. Bloom, Andrew R. Heyer and Dean C. Kehler. Trimaran Capital Partners manages Trimaran Fund II, a $1.043 billion private equity fund, that concentrates on investments in the equity of private companies in the United States and Western Europe. In addition to its private equity funds, Trimaran Capital Partners also manages, through Trimaran Advisors, a portfolio of structured investment funds consisting of two collateralized debt obligation funds, Caravelle Investment Fund and Caravelle Investment Fund II and two loan investment vehicles. Trimaran Capital Partners is headquartered in New York.

For more information, visit www.trimarancapital.com


Moderator:    

Ernst & Young  

        David Mackinnon, Partner, Ernst & Young         

      David is a Partner in the New York Office of Ernst & Young’s Transaction Support practice.  He has spent over ten years providing advisory services including due diligence, transaction structuring, and portfolio monitoring to some of the largest and most recognizable private equity funds in the country. Prior to that, David spent seven years in Ernst & Young’s audit practice working primarily with large SEC clients involved in merger and acquisition activities. David’s transaction experience covers a broad range of industries including telecommunications, high technology, industrial manufacturing, healthcare, energy and extractive industries, consumer products and aerospace.  His experience has typically involved more complex transactions such as those involving international businesses, corporate carve-outs, high-yield financings, industry consolidations and multi-product line targets. David has frequently spoken on due diligence and accounting structuring matters at private equity industry seminars.  He is a certified public accountant with 16 years of experience.  David received and his Masters in Accounting from the Northeastern University Graduate School of Professional Accounting in 1985 his B.A. from Middlebury College in 1983.

For more information, visit www.ey.com  

___________________________________________________________________

        Mr. Klausner is a General Partner at Domain Associates, a venture capital firm specializing in early stage     life sciences investments.  Klausner joined Domain in 1990 after earning an M.B.A. at the Stanford University Graduate School of Business.  While attending business school, he completed summer internships emphasizing corporate planning and market research functions at ImClone Systems Corp. and Neurogen Corp., two start‑up biopharmaceutical companies that have since gone public.  Previously, Klausner had spent six years at Bio/Technology magazine (now Nature Biotechnology), where as Senior Editor he researched and prepared over 200 articles concerning scientific and business aspects of applied biology.  He has also performed consulting projects for the U.S. Office of Technology Assessment, Arthur D. Little Decision Resources, and a variety of pharmaceutical and biotechnology companies.  Klausner's undergraduate degree from Princeton University is in Biology.  He currently serves on the Board of Directors of several privately held biopharmaceutical and medical device companies, including ATI Medical, Santarus, Tandem Medical, and X-Ceptor Therapeutics.

          With offices in Princeton, NJ, and Laguna Niguel, CA, Domain Associates is a venture capital management company that provides seed- and early‑stage financing and organizational support to technology-based companies focused on life sciences.  Total funds managed or advised exceed $900 million.  Specific areas of investment interest include biopharmaceuticals, medical devices, drug discovery services, bio‑instrumentation, diagnostics, new materials as applied to healthcare, eHealth, and healthcare information systems. With demonstrated expertise in technology assessment, strategic planning, operations, and finance, Domain’s partners have been involved in the creation and development of more than 100 life sciences ventures.  Today, these companies generate total annual revenues of greater than $5 billion, employ more than 20,000 people, and have a combined market capitalization exceeding $100 billion.  

For more information, visit www.DomainVC.com
                                             

Healthcare Ventures

         Dr. Eric Aguiar, General Partner, Healthcare Ventures

        Healthcare Ventures is one of the world's largest venture capital firms specializing in health care, making investments in early stage and emerging growth companies that have the potential for exceptional growth. The firm has successfully raised and managed five funds in the past fifteen years. HealthCare Ventures is committed to creating new biopharmaceutical companies by effectively linking important advances in medicine with
successful and experienced management teams. Since its formation, HCV has created leading biopharmaceutical com-
panies in strategically important fields such as genetic therapy, genomic sciences, drug discovery and delivery, neuroscience, cancer therapy, and organ and cellular transplantation. An important success factor is HCV's ability to quickly and accurately analyze the commercial value of a scientific discovery. In this regard, our renowned Scientific Advisory Board and our extensive network of scientific collaborators and industry executives provides us with a distinct advantage.

For more information, visit www.hcven.com


Perseus-Soros Biopharmaceutical Fund

        Dr. Drew Schiff, Associate, Perseus-Soros Biopharmaceutical Fund

      Andrew N. Schiff is an Associate of the Perseus-Soros Biopharmaceutical Fund. Over the last ten years, Dr. Schiff has practiced internal medicine at The New York Presbyterian Hospital where he serves as an Assistant Professor of Medicine. He has also been a partner of a family-run investment fund, Kuhn, Loeb & Co., and a consultant for Northwood Ventures, a Long Island, New York based venture group. In these capacities, he has been responsible for identifying investment opportunities and raising additional financing for portfolio companies. Dr. Schiff serves as director of Adams Laboratories. Dr. Schiff is a member of the Board of Directors of the Deerfield Academy and the Henry Street Settlement of New York. He is also a member of the Board of Overseers of the Brown University School of Medicine. Dr. Schiff has a B.S. in neuroscience, awarded with honors, from Brown University, a M.D. from Cornell University Medical College and an M.B.A. from Columbia University.

        Perseus-Soros Biopharmaceutical Fund was established in 1999 by affiliates of Perseus, L.L.C. (Perseus) and Soros Private Funds Management, LLC (SPFM) to make investments in life science companies developing biopharmaceutical products and creating businesses based on advanced life science technologies. Perseus, L.L.C. is a merchant back and private equity fund management company headquartered in Washington, D.C. operating funds with over $1 billion of private capital. Perseus has extensive experience in structuring financial investments. Perseus' funds include Perseus 1996, Perseus Capital, Perseus 2000, and the Perseus Acquisition/Recapitalization Fund. Perseus also has extensive investment effort in advanced technologies in the energy field. SPFM is an affiliate of Soros Fund Management, L.L.C. (SFM) based in New York and London. The Soros organization has been one of the world’s most successful investors during the past 21 years in a variety of markets, securities, investment vehicles (including private equity), and industries in more than 45 countries.

For more information, visit www.psbiofund.com


Sprout Group

      Ron Hunt, Director, Sprout Group

    Ron Hunt is a Director at the Sprout Group, where he focuses on life sciences and health care technology investing.  Ron joined Sprout in January, 1998.Previously, he worked as a consultant to the pharmaceutical industry and other healthcare clients for The Health Care Group and Coopers & Lybrand. Ron also worked for a combined eight years at Johnson & Johnson and SmithKline Beecham in a variety of sales, marketing, and strategic planning positions. Ron received his MBA from the Wharton School of the University of Pennsylvania and a BS from Cornell University. Ron serves on the Board of Directors of Protedyne, Inc., Lathian Systems, Phase Forward, Epotec, Inc., Microban International, and Space Fitters. 

        Since raising our first venture fund of $12 million more than 30 years ago, Sprout has invested in more than 350 companies whose combined revenues now exceed $50 billion. Our current fund, Sprout Capital IX, totals $1.6 billion. Sprout is committed to building a portfolio that is foucsed on technology investments and is balanced by stage and industry, including early stage, growth, mezzanine, and buyout investments in the Datacom & Telecom, E-Commerce, Services, Healthcare Technology, Software and Technology industries. While we are not typically providers of seed capital, Sprout is very active as early stage investors. Sprout Capital IX was raised in late 2000, and is $1.6 billion.  The fund is capitalized primarily by commitments from large corporate pension funds, public funds, insurance companies, endowments, and other private investors - 60% of whom have invested in previous Sprout funds. Our roster of limited partners includes AIG, Brinson Partners, The Common Fund, Equitable Life, Harbourvest, St. Paul Fire & Marine, and Toronto Dominion Bank, as well as the pension funds of BP(ARCO), Honeywell, the states of Michigan, Virginia, Washington, and others.

For more information, visit www.sproutgroup.com


Moderator:

JP Morgan Partners

         Damion E. Wicker, M.D., Partner, JP Morgan Partners

         Dr. Wicker is currently a Partner with JPMorgan Partners. J.P. Morgan Partners (JPMP), formerly Chase Capital Partners, is a global partnership with over $24 billion under management. It is a leading provider of private equity and has closed over 1,600 individual transactions since its inception in 1984. Dr. Wicker received a B.S. with honors from M.I.T in 1983, an M.D. from Johns Hopkins in 1987, and holds an MBA from the Wharton School of the University of Pennsylvania. Prior to joining JPMP, Dr. Wicker was President of Adams Scientific and held positions with MBW Venture Partners and Alexon, Inc. Dr. Wicker was also a Commonwealth Fund Medical Fellow for the National Institute of Health. He is currently a member of the NVCA Life Science Group Board and the Board of Trustees of the New York Academy of Medicine. Dr. Wicker currently is also a Director of Genomic Solutions, Eyetech Pharmaceuticals, MediChem Life Sciences, Neuron Therapeutics, Optiscan, Transurgical, Vitagen and V.I. Technologies.

        JP Morgan Partners ("JPMP") is a global private equity organization which provides equity and mezzanine capital financing to private and public companies. We invest throughout the entire life cycle of the business development process. Our investment mandate permits maximum flexibility in supporting the equity needs of businesses worldwide. With over 160 investment professionals, JPMP has invested directly in over 30 countries through our seven offices and over 30 strategic relationships. JPMP currently manages an $24 billion portfolio

For more information, visit www.JPMorganPartners.com. 

___________________________________________________________________

Moderator: 

Heller Ehrman

        Stephen M. Davis, Partner, Heller Ehrman

        Stephen M. Davis has practiced corporate and securities law since 1979. Mr. Davis joined the firm of Werbel & Carnelutti in 1983, where he became partner in 1987. Werbel & Carnelutti combined with Heller Ehrman White & McAuliffe LLP in 1999. Mr. Davis is co-chair of Heller Ehrman’s Information Technology National Practice Group and Emerging Companies Practice Group.  Mr. Davis has extensive experience in several areas of corporate practice with a focus on venture capital, corporate finance and securities, and mergers and acquisitions. He has represented clients in transactions ranging from start-up financings to billion dollar plus public offerings and has counseled companies in diverse industries such as Internet infrastructure, application and services, broadband, new media, wireless technologies, computer hardware and software, e-health, biotech, environmental and energy, venture financing, medical services, consumer products retailing, and investment management. Mr. Davis has represented issuers and underwriters in numerous initial public offerings and acts as outside general counsel to several public and private companies.  Mr. Davis graduated cum laude from Columbia College, and received his JD from Columbia Law School (Harlan Fiske Stone Scholarship).

         Helping clients shape the new economy is the primary mission of lawyers at Heller Ehrman. As a full-service firm representing clients from the largest publicly traded companies to emerging private enterprises, the breadth and quality of service we provide is unmatched by our competitors.  Our offices are located in San Francisco, Silicon Valley, Los Angeles, San Diego, Seattle, Portland, Anchorage, New York, Washington, D.C., Montgomery Co., MD, Hong Kong and Singapore. At 544 lawyers, we are one of the fastest growing firms in the country. Heller Ehrman lawyers service clients throughout the biotech, telecommunications, securities, banking and computer industries. Within 15 national practice groups, our lawyers are leaders in some of today’s hottest practice areas, including intellectual property, life sciences, antitrust, mergers and acquisitions and emerging companies. We have a tradition of service that extends not only to paying clients but to communities and to individuals who cannot afford much needed legal services. Firmwide, Heller Ehrman attorneys contribute thousands of hours each year to community, nonprofit and public interest organizations—dedication that earned us the American Bar Association’s 2000 Pro Bono Publico Award.  As we move into the new millennium, we will expand our services and continue the traditions we began more than a century ago. Our attorneys will carry forward proudly their commitment to client services, the legal profession and the public interest as a whole. 

For more information, visit www.hewm.com.
___________________________________________________________________

Panel IV  Private Equity Buyout Experts And Venture Capitalists Compare And Contrast 
           Exit Strategies: Buyouts,  Roll-ups, M&A, PIPE,  And The Return Of The IPO Markets

Panelists:  

ABS Capital Partners

       Laura L. Witt, General Partner, ABS Capital Partners

        Laura L. Witt joined ABS Capital Partners in 1997. She focuses on investment opportunities in the supply chain management, customer relationship management and e-commerce sectors, and also counsels ABS portfolio companies on major strategic issues. Witt was the lead partner for ABS's recent investment in YOUcentric, a provider of Java-based eBusiness Relationship Management software, and was formerly a member of YOUcentric's board of directors.  Witt also serves on the board of directors of Familymeds, and has been actively involved with ABS's investments in ChannelWave and other portfolio companies. Prior to joining ABS, Witt was a senior consultant at Monitor Company, a strategy consulting firm advising clients on growth strategies, the assessment of new technologies and markets, corporate restructurings and mergers and acquisitions.  From 1990-1992, Witt was a consultant for Oliver, Wyman & Company, a strategy consulting firm for financial services companies.  Witt received a B.A. with high honors in political science from Princeton University and an M.B.A. from the Wharton School of the University of Pennsylvania, where she was named a Palmer Scholar. She has spoken on private equity financing and ABS's investment process as a member of panel discussions sponsored by investment banks and the Northern Virginia Technology Council.        

        Credit Suisse First Boston is the leading full-service investment bank for technology companies worldwide.   The CSFB Technology Group provides strategic solutions for clients with a full suite of financial services, including private placements, IPO’s, merger and acquisition advice, common stock offerings, convertibles, straight debt, derivatives, leveraged lending and private client services.  For the second consecutive year, CSFB achieved #1 market share in both financings as well as mergers and acquisitions transactions for the technology industry.  In 2000 CSFB Technology Group lead-managed 101 IPO and follow-on transactions totaling $23 billion, 53 private placement transactions totaling $2.9billion and advised on 146 M&A transactions valued at $309 billion. The technology group has an award winning research team with 54 senior analysts worldwide covering over 500 companies. In the U.S. last year, CSFB’s technology analysts were once again recognized by the industry with 7 Institutional Investor All-America Research team awards, 8 Greenwich Survey top-five rankings and 22 Reuters Survey top five rankings.  They also garnered 3 Wall Street Journal “Best of the Street 2000” awards.  In Europe, CSFB’s Software & Computer Services and Information Technology research teams were ranked #1 by Reuters. The European team also claimed 2 Institutional Investor awards and 4 Extel awards.  Institutional Investor and The Asset 2000 ranked CSFB’s All-Asia Technology Research #1.  The Asia team also received 3 Asiamoney top-three rankings. With over 600 employees dedicated to technology banking based in Palo Alto, San Francisco, New York, Boston, London, Hong Kong and Sao Paulo, CSFB offers unparalleled client service and industry expertise.

For more information, visit www.csfb.com.


JW Seligman

        Tom Hirschfeld, Managing Director, JW Seligman

        Thomas P. Hirschfeld is Managing Director, Venture Capital Investments, Seligman Technology Group, for J. & W. Seligman & Co. Incorporated.  Mr. Hirschfeld, who has more than 14 years of investment experience, focuses primarily on late-stage technology investments. He is based in the Group’s New York office.   Mr. Hirschfeld joined Seligman in January 2001. Previously, he was with Patricof & Co. Ventures, where he most recently served as General Partner, making venture investments in early-stage companies.  Prior to Patricof, he worked as an investment banker at Salomon Brothers from 1986 to 1994, specializing in media and technology companies.  He also served as Assistant to the Mayor of New York City during 1994, leading a thirty-person economic policy group.  Mr. Hirschfeld received his graduate degree in Economics and Politics from Balliol College, Oxford University, which he attended on a Marshall Scholarship. He graduated magna cum laude in Classics from Harvard College.  Mr. Hirschfeld is also the author of three nonfiction books totaling over a million copies in print: Business Dad: How Good Businessmen Can Make Great Fathers (and Vice Versa), How to Master the Video Games, and How to Master Home Video Games.

     Founded in 1864, JW Seligman & Co. is one of the nation's oldest investment firms. Investment management is our core business, and we are 100% employee owned. As of June 30, 2001, we managed over $31 billion in assets for institutions -- including public funds, corporations, Taft-Hartley plans, endowments and foundations -- and investment companies.  Today, as we enter the 21st century, Seligman is recognized as a leader in the field of technology research, analysis and investment. From venture capital to established large-cap companies, we are one of the largest investors in the communication, information and technology sectors. As of June 30, 2001 we have more than $9.7 billion invested in technology companies located throughout the world.

For more information, visit www.jwseligman.com.

Pequot Ventures

        Erik Jansen, Principal, Pequot Ventures 

      Erik Jansen co-manages the firm's venture capital funds. Previously, he was co-founder and principal of Digital Media Capital, L.L.C., a private venture capital firm based in Stamford, CT where he invested in seed and early stage Internet and Intranet-related software and communications companies. Prior to that, Mr. Jansen was senior vice president at S.N. Phelps & Company, a Greenwich, CT based merchant banking firm. Mr. Jansen brought more than 15 years of investment and operational experience in the venture capital industry to Pequot. He received a B.B.A. in International Business from the Netherlands School of Business at Nijenrode, and a M.B.A in Finance from the Edwin L. Cox School of Business at Southern Methodist University in Dallas. Mr. Jansen serves on the Board of Directors of AsiaDemand, Accruent Software, OutlookSoft, Tian Software Company and Vcommerce and is an observer on the Board of Directors of Nxtwave Communications, OuterForce Systems and Syncra Systems.

       Pequot Ventures is the direct venture investment arm of Pequot Capital Management, focused on today's most dynamic startup and growth stage companies in technology, telecommunications and healthcare. Pequot Ventures creates value by bringing energy and substantial sector expertise to its portfolio companies through the collective intellectual capital, deep operating experience and extensive network of its investment team.  The firm leverages its unique multi-billion dollar presence across both public and private equity markets to help build competitive, sustainable  businesses in fast changing environments and throughout their lifecycles.

For more information, visit www.pequotcap.com


Moderator:   

        Alexander D. Lynch, Partner, Wilson Sonsini Goodrich & Rosati

        Mr. Lynch's practice focuses on the representation to telecommunications, software, hardware, biotechnology, medical device and other emerging growth companies, as well as leading investment banks and venture capital firms. Mr. Lynch has extensive experience in venture capital financings, initial public offerings, follow-on offerings, corporate partnering transactions, strategic investments, private placements and mergers and acquisitions. Mr. Lynch served as lead counsel on many of the most prominent technology transactions in New York's "Silicon Alley" and, over the last few years, has helped Silicon Alley companies raise over $3.0 billion in venture and public equity capital. During that period, he also advised Silicon Alley companies on mergers and acquisitions valued at over $2 billion. Mr. Lynch received a J.D. from Columbia University in 1987 and a B.S., cum laude, from Tulane University in 1983, where he was the recipient of the Aaron Hartman Award. Prior to joining Wilson Sonsini Goodrich & Rosati, he was a partner at Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP from July 2000 to February 2001. Mr. Lynch was also a partner in the New York office of Brobeck, Phleger & Harrison LLP, where he was the co-chair of the Public Offerings Practice Group and a member of Brobeck's Management and Investment Committees. In addition, from February to June 2000, Mr. Lynch was Vice President - Strategic Development at TradeOut, Inc. Mr. Lynch is a member of the New York State Bar and the American Bar Association. Mr. Lynch also served on the Board of Directors of the Knot, Inc., a publicly traded online wedding resource destination. Admitted to bar: 1988, New York.

        Wilson Sonsini Goodrich & Rosati (WSGR) is the leading law firm representing technology companies at all stages of their growth, as well as the investment banks and venture capital firms that finance them. Over the past four decades, the firm has established its reputation by having an unmatched knowledge of its clients’ industries, as well as deep and long-standing contacts throughout the technology sector. WSGR distinguishes itself by taking the time to understand its clients’ business needs and by providing a full range of legal services designed to scale with their growth. The firm is equipped and experienced in helping to start entrepreneurial ventures, successfully take them through their Initial Public Offerings and follow-on financings, and then counsel them on a myriad of business issues – including taxation, intellectual property, mergers and acquisitions, and litigation.

For more information, visit www.wsgr.com

___________________________________________________________________